FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BAILEY DON M						2. Issuer Name and Ticker or Trading Symbol QUESTCOR PHARMACEUTICALS INC [QCOR]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title Other (specify below))						
(Last) (First) (Middle) 1300 NORTH KELLOGG DRIVE SUITE D					04	3. Date of Earliest Transaction (Month/Day/Year) 04/24/2013									President and CEO					
(Street) ANAHEIM CA 92807				_ 4. I _	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)												1 013011					
			le I - I			_				ed, D	isposed o			ially	1					
1. Title of Security (Instr. 3)			2. Transact Date (Month/Day		ar) 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		(4) or		3, 4 and	3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	V	Amount	(D)	Price		(Instr. 3	and 4)				
Common Stock				04/24/2013				М		9,969	A	\$5.	.09	108,969(1)			I	Held by the Bailey 1995 Family Trust		
Common Stock 04/2				04/24/2	2013				S		9,969	D	\$30.0	032 ⁽⁴⁾	99,0	99,000 ⁽¹⁾		I	Held by the Bailey 1995 Family Trust	
Common Stock 0				04/25/2			М		10,031	A	\$5.	.09 109		031(1)		I	Held by the Bailey 1995 Family Trust			
Common Stock 04/25/				2013	13			S		10,031	D	\$30.0	\$30.064 ⁽⁵⁾		99,000(1)		I	Held by the Bailey 1995 Family Trust		
		1	Table								posed of, , convertil				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Conversion Date (Month/Day/Year) Price of Derivative		3A. Deemed 4. Execution Date, To		4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			cisable and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		ount 8	. Price of Perivative Pecurity Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
						v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amo or Num of Shar	ber						
Stock Option (right to buy) ⁽²⁾	\$5.09	04/24/2013			M			9,969	(3)		02/05/2018	Common Stock	9,969		\$0	263,370 ⁽¹⁾		I	Held by the Bailey 1995 Family Trust	
Stock Option (right to buy) ⁽²⁾	\$5.09	04/25/2013		1				10,031	(3)		02/05/2018	Common Stock	ⁿ 10,0)31	\$0	253,339 ⁽¹⁾		I	Held by the Bailey 1995 Family Trust	

- 1. As of the date of this Form 4, the reporting person holds Questcor Pharmaceuticals, Inc. stock options to purchase 1,478,339 shares of common stock; of such amount, 1,111,254 shares are fully vested and exercisable. The reporting person also holds 390,317 shares of Questcor Pharmaceuticals, Inc. common stock, of which 291,317 shares are held directly by the reporting person.
- 2. Options were granted under the Questcor Pharmaceuticals, Inc. 2006 Equity Incentive Award Plan.
- 3. The option was granted on 02/06/2008 for the right to buy 500,000 shares of common stock of the Issuer. The option provided for monthly vesting over 48 months from the date of grant, with a 12-month cliff, whereby no options vested until after the twelfth month from the date of the grant. A total of 253,339 shares remain unexercised under this option grant.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$30.00-\$30.05, inclusive. The reporting person undertakes to provide Questcor Pharmaceuticals, Inc., any security holder of Questcor Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$30.00-\$30.175, inclusive. The reporting person undertakes to provide Questcor Pharmaceuticals, Inc., any security holder of Questcor Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.

Remarks

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person in the second quarter of 2012 and effective 90 days post-adoption, which plan controls the exact dates and amounts of sales.

<u>/s/ Don M. Bailey</u> <u>04/26/2013</u>

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.